Daflon 500 mg: Symptoms and Edema

Abstract

Patients suffering from any class of the Clinical, Etiological, Anatomical, Pathophysiological (CEAP) classification of chronic venous disease (CVD) may be symptomatic (C0s-C6s). Leg heaviness, discomfort, itching, cramps, pain, paresthesia, and edema (C3) are the most frequent manifestations of CVD and a major reason for medical consultation. Daflon 500 mg (micronized purified flavonoid fraction [MPFF]) is an effective treatment for symptoms and edema in CVD as demonstrated in several randomized controlled studies. A 2-month, double-blind study in 40 patients established the superiority of Daflon 500 mg over placebo with regard to symptoms and objective signs. This was confirmed in another double-blind, placebo-controlled trial (2 months’ treatment, 160 patients), and in the Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids (RELIEF) study. The latter included 5,052 patients in 23 countries, using a visual analog scale for evaluating pain, leg heaviness, cramps, and a sensation of swelling. All symptoms showed significant and progressive improvement. The quality-of-life results (scores on the ChronIc Venous Insufficiency quality of life Questionnaire [CIVIQ]) paralleled those of symptoms. The decrease in the ankle and calf circumferences was significantly greater (p<0.001) in the group of patients treated with Daflon 500 mg in two studies, and correlated well with the improvement in the sensation of swelling (p<0.001). This was confirmed with more sophisticated measurement techniques as in the RELIEF study or in a trial assessing edema with an optoelectronic volumeter in 20 patients. A further double-blind, randomized, controlled study established a statistically significant difference in favor of Daflon 500 mg in comparison with diosmin, both on symptoms and edema. The therapeutic efficacy of Daflon 500 mg on CVD symptoms and edema has been demonstrated in double-blind, randomized, controlled studies. Further studies using a new approach may define the most precise and validated methodology for application in future research in phlebology.

Get full access to this article

View all access options for this article.

References

Eklof B

Rutherford RB

Bergan JJ

et al

; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification: Revision of the CEAP classification for chronic venous disorders: Consensus statement. J Vasc Surg 40:1248-1252, 2004.

Ramelet AA

Monti M

: Phlebology: The Guide. Paris: Elsevier, 1999.

Kahn SR

M’Ian CE

Lamping DL

et al

: Relationship between clinical classification of chronic venous disease and patient-reported quality of life: Results from an international cohort study. J Vasc Surg 39:823-828, 2004.

Ruckley CV

Evans CJ

Allan PL

et al

: Chronic venous insufficiency: Clinical and duplex correlations. The Edinburgh vein study of venous disorders in general population. J Vasc Surg 36:520-525, 2002.

Saharay M

Shields DA

Georgionnos SN

et al

: Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 15:342-349, 1998.

Saharay M

Shields DA

Porter JV

et al

: Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 26:265-273, 1997.

Bauersachs J

Fleming I

Busse R

: Pathophysiology of chronic venous insufficiency. Phlebology 11:16-22, 1996.

Takase S

Lerond L

Bergan JJ

et al

: The inflammatory reaction during venous hypertension in the rat. Microcirculation 7:41-52, 2000.

Takase S

Pascarella L

Bergan JJ

et al

: Hypertension-induced venous valve remodeling. J Vasc Surg 9:1329-1334, 2004.

10.

Danziger N

: Pain in peripheral neuropathies: Physiopathology, clinical evaluation and medical management. Rev Neurol 157:1565-1569, 2001.

11.

Johnson KO

: The roles and functions of cutaneous mechanoreceptors. Curr Opin Neurobiol 11:455-461, 2001.

12.

Bouskela E

Cyrino FZGA

Lerond L

: Leukocyte adhesion after oxidant challenge in the hamster cheek pouch microcirculation. J Vasc Res 36(suppl 1):11-14, 1999.

13.

Shoab SS

Porter J

Scurr JH

et al

: Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease—a prospective study. Eur J Vasc Endovasc Surg 17:313-318, 1999.

14.

Friesenecker B

Intaglietta M

Tsai AG

et al

: Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: In vivo observations in the hamster skin fold. Int J Microcirc 14:50-55, 1994.

15.

Korthuis RJ

Gute D

: Adhesion molecule expression in postischemic microvascular dysfunction: Activity of a micronized purified flavonoid fraction. J Vasc Res 36(suppl 1):15-23, 1999.

16.

Danielson G

Jungbeck C

Peterson K

et al

: A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 3:73-76, 2002.

17.

Takase S

Pascarella L

Lerond L

et al

: Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 28:484-493, 2004.

18.

Chassignolle JF

Amiel M

Lanfranchi G

et al

: Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse fonctionnelle. JIM 99(suppl):32-35, 1987.

19.

Gilly R

Pillion G

Frileux C

: Evaluation of a new vasoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: A double-blind, placebo-controlled study. Phlebology 9:67-70, 1994.

20.

Jantet G

and the

RELIEF Study Group

: RELIEF study: First consolidated European data. Angiology 51:31-37, 2000.

21.

Jantet G

and the

RELIEF Study Group

: Chronic venous insufficiency—worldwide results of the RELIEF study. Angiology 53:245-256, 2002.

22.

Launois R

: Construction and validation of quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res 5:539-554, 1996.

23.

Coleridge-Smith P

Lok C

Ramelet AA

: Venous leg ulcer: A meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 30:198-208, 2005.

24.

Ramelet AA

: Meta-analysis of clinical trials carried out with Daflon 500 mg in patients with leg ulcers of venous origin. Study report 2005.

25.

Cospite M

Dominici A

: Advantage of micronisation of Daflon 500 mg compared with a simple diosmine in the treatment of venous insufficiency. Double blind study. Phlébologie 51:243-247, 1998.

26.

Berard A

Kurz X

Zuccarelli F

et al

: Reliability study of the Leg-O-Meter, an improved tape measure device, in patients with chronic venous insufficiency of the leg. Veines group. Angiology 49:169-173, 1998.

27.

Blume J

Langenbahn H

De Champvallins M

: Quantification of oedema using the volometer technique: Therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology 7(suppl 2):37-40, 1992.